"Ritonavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.
| Descriptor ID |
D019438
|
| MeSH Number(s) |
D02.886.675.653 D03.383.129.708.653
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ritonavir".
Below are MeSH descriptors whose meaning is more specific than "Ritonavir".
This graph shows the total number of publications written about "Ritonavir" by people in this website by year, and whether "Ritonavir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 1 | 4 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 4 | 0 | 4 |
| 2010 | 1 | 0 | 1 |
| 2011 | 4 | 0 | 4 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 1 | 3 |
| 2016 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 0 | 2 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ritonavir" by people in Profiles.
-
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014 Jul; 14(7):572-80.
-
Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies. AIDS. 2014 Mar 13; 28(5):791-3.
-
Early outcomes of darunavir- and/or raltegravir-based antiretroviral therapy in children with multidrug-resistant HIV at a pediatric center in Botswana. J Int Assoc Provid AIDS Care. 2013 Mar-Apr; 12(2):90-4.
-
Metabolomic screening and identification of the bioactivation pathways of ritonavir. Chem Res Toxicol. 2011 Dec 19; 24(12):2109-14.
-
Nordihydroguaiaretic acid (NDGA) inhibits ritonavir-induced endothelial dysfunction in porcine pulmonary arteries. Med Sci Monit. 2011 Nov; 17(11):BR312-318.
-
CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir. Drug Metab Dispos. 2012 Jan; 40(1):18-24.
-
Natural antioxidant dihydroxybenzyl alcohol blocks ritonavir-induced endothelial dysfunction in porcine pulmonary arteries and human endothelial cells. Med Sci Monit. 2011 Sep; 17(9):BR235-41.
-
Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May; 38(5):871-8.
-
Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy. Pediatr Infect Dis J. 2009 Dec; 28(12):1127-9.
-
The soybean isoflavonoid equol blocks ritonavir-induced endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial cells. J Nutr. 2010 Jan; 140(1):12-7.